Cantor Fitzgerald Maintains a Buy Rating on Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best biotech stocks with high potential.
Crinetics Pharmaceuticals Inc. (CRNX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Driehaus Capital Richard Driehaus | 6,400,025 | $184,064,719 | +3% | 1.47% |
| 2. | Farallon Capital Thomas Steyer | 4,646,098 | $133,621,778 | +1% | 0.58% |
| 3. | EcoR1 Capital Oleg Nodelman | 4,288,120 | $123,326,331 | 7.3% | |
| 4. | Point72 Asset Management Steve Cohen | 1,998,161 | $57,467,104 | +157% | 0.11% |
| 5. | Siren L.L.C. Raymond Debbane | 1,688,611 | $48,564,452 | 2.51% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.06 | 5,000 | $110,300.00 | 5,000 | 2023-06-08 | Filing | |
| $22.22 | 157,515 | $3,499,983.30 | 5,321,032 | 2022-04-18 | Filing | |
| $19.80 | 1,200,000 | $23,760,000.00 | 5,163,517 | 2021-10-25 | Filing | |
| $16.44 | 304,136 | $4,999,995.84 | 3,963,517 | 2021-04-08 | Filing | |
| $13.10 | 4,000 | $52,400.00 | 4,000 | 2020-12-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $41.81 | 5,000 | $209,050.00 | 66,270 | 2025-10-01 | Filing | |
| $45.00 | 4,000 | $180,000.00 | 106,000 | 2025-09-26 | Filing | |
| $44.75 | 16,000 | $716,000.00 | 22,836 | 2025-09-26 | Filing | |
| $32.10 | 5,000 | $160,500.00 | 96,270 | 2025-09-02 | Filing | |
| $30.43 | 30,000 | $912,900.00 | 66,270 | 2025-08-22 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 34,694 | $1,445,005 | 0% | |
| 2. | 21,100 | $878,815 | 0.12% | |
| 3. | 12,338 | $513,878 | 0% | |
| 4. | 842 | $35,069 | 0% | |
| 5. | 233 | $9,704 | 0% |
News See All
14 Biotech Stocks with High Potential
Healthcare was the second worst performer this year, with pharma and biotech companies under pressure.
JMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-Approval
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is among the best fast money stocks to buy now.
JPMorgan Lifts PT on Crinetics Pharmaceuticals (CRNX) to $52 From $53, Keeps an Overweight Rating
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best strong buy stocks to invest in according to Wall Street.
11 Best Fast Money Stocks to Buy Now
In this fast-paced world, most people have become impatient. Everyone is drawn to whatever delivers quick results, whether it be fast fame or fast money.
Crinetics Pharma (CRNX) Flies 35% Higher on FDA Approval of Acromegaly Drug
We recently published 10 Big Names With Explosive Gains That Investors Can’t Ignore. Crinetics Pharmaceuticals, Inc.
12 Best Strong Buy Stocks to Invest in According to Wall Street
On September 26, Peter Boockvar, chief investment officer at One Point BFG Wealth Partners, appeared on CNBC to talk about the likelihood of the Federal Reserve’s interest rate cuts, new inflation data...
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q2 2025 Earnings Call Transcript
Operator: Welcome to Crinetics Pharmaceuticals Second Quarter 2025 Financial Results Conference Call.
Crinetics Pharmaceuticals, Inc. (CRNX)' Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data
Crinetics Pharmaceuticals, Inc.
11 Best Future Stocks to Buy Now
Over the past year, investors have poured money into cutting-edge technologies like artificial intelligence and electric cars.